Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2024/2025 influenza season

as of November 9, 2026

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	3 (0.3%)	25 (1.2%)	25 (1.2%)	0	0	707 (100%)	2 (0.8%)	0	0	0	0	352 (100%)	0	0	0	0	0
Number of viruses tested	864	2,146	2,146	345	345	707	260	186	186	186	186	352	195	156	156	156	156
Number of viruses reported	3,935						673						669				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.